Article ID Journal Published Year Pages File Type
3316329 Pancreatology 2016 6 Pages PDF
Abstract
Treatment of pancreatic cancer patients with AXP107-11 in combination with gemcitabine resulted in a favorable PK-profile with high serum levels without signs of either hematological or non-hematological toxicity. Accordingly, we suggest further studies with AXP107-11 in pancreatic cancer patients.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Gastroenterology
Preview
A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer
Authors
, , , , , , ,